§ 01 Overview
Overview
Combination oral capsule stacking BPC-157 and KPV for gut mucosal healing and anti-inflammatory effects.
Component data is preclinical. The specific combo has no controlled trials.
§ 02 Mechanism
Mechanism of action
BPC-157 promotes mucosal repair and angiogenesis while KPV suppresses NF-κB-driven inflammation. The combination targets both structural repair and inflammatory drivers in IBD-like conditions.
- 01Targeted gut repair + anti-inflammatory
- 02Convenient oral delivery for GI indications
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 500 mcg 1–2x daily
- Route
- Oral
- Frequency
- Daily
- Cycle
- 4–8 weeks
§ 04 Evidence
Evidence & research
Component data is preclinical. The specific combo has no controlled trials.
FDA Status
Not FDA-approved. BPC-157 on FDA Negative List.
§ 05 Stacks
Common stacks
§ 07 Sourcing
Sourcing & supply
Regulatory status
Restricted from compounding
Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Generally well tolerated
Contraindications
None specified.